CDKN2A and cancer: This observation is consistent with the increased sensitivity to palbociclib observed in 544 cancer cell lines in association with CDKN2A inactivation by DNA methylation and with the limited capacity of current CDK4/6i to inhibit its target when it is bound to INK4 proteins or to p27Kip1 14,32,47.